Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Receives Average Rating of "Buy" from Analysts

Shares of Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Get Free Report) have earned a consensus rating of "Buy" from the six analysts that are currently covering the firm, MarketBeat reports. Five equities research analysts have rated the stock with a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month price target among analysts that have updated their coverage on the stock in the last year is $23.80.

A number of brokerages have weighed in on LXEO. Royal Bank of Canada reissued an "outperform" rating and issued a $24.00 price target on shares of Lexeo Therapeutics in a report on Tuesday, August 13th. Chardan Capital upped their price target on shares of Lexeo Therapeutics from $23.00 to $25.00 and gave the company a "buy" rating in a report on Wednesday, November 13th. Leerink Partners cut their price target on shares of Lexeo Therapeutics from $20.00 to $19.00 and set an "outperform" rating for the company in a report on Wednesday, November 13th. Finally, HC Wainwright upped their price target on shares of Lexeo Therapeutics from $21.00 to $23.00 and gave the company a "buy" rating in a report on Thursday, November 14th.

Insider Buying and Selling at Lexeo Therapeutics

In other Lexeo Therapeutics news, CEO Richard Nolan Townsend sold 5,000 shares of the firm's stock in a transaction on Tuesday, September 10th. The shares were sold at an average price of $10.65, for a total value of $53,250.00. Following the sale, the chief executive officer now directly owns 120,695 shares in the company, valued at $1,285,401.75. This trade represents a 3.98 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders have sold a total of 12,500 shares of company stock worth $113,300 over the last 90 days. Insiders own 4.50% of the company's stock.

Institutional Trading of Lexeo Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Janus Henderson Group PLC boosted its position in shares of Lexeo Therapeutics by 9.0% during the 1st quarter. Janus Henderson Group PLC now owns 2,540,785 shares of the company's stock valued at $39,802,000 after acquiring an additional 210,047 shares in the last quarter. American International Group Inc. bought a new position in shares of Lexeo Therapeutics during the 1st quarter worth approximately $79,000. Vanguard Group Inc. boosted its stake in Lexeo Therapeutics by 15.8% in the 1st quarter. Vanguard Group Inc. now owns 481,755 shares of the company's stock valued at $7,554,000 after buying an additional 65,573 shares in the last quarter. Bank of New York Mellon Corp grew its position in Lexeo Therapeutics by 12.3% in the second quarter. Bank of New York Mellon Corp now owns 31,806 shares of the company's stock valued at $510,000 after acquiring an additional 3,483 shares during the period. Finally, Rhumbline Advisers boosted its stake in shares of Lexeo Therapeutics by 37.3% in the 2nd quarter. Rhumbline Advisers now owns 13,357 shares of the company's stock valued at $214,000 after purchasing an additional 3,627 shares in the last quarter. 60.67% of the stock is currently owned by institutional investors and hedge funds.

Lexeo Therapeutics Stock Performance

Shares of Lexeo Therapeutics stock traded up $0.50 during trading on Thursday, hitting $7.83. 228,868 shares of the stock were exchanged, compared to its average volume of 250,042. The stock's fifty day moving average is $8.48 and its 200 day moving average is $11.86. The stock has a market cap of $258.91 million and a PE ratio of -2.48. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.95 and a current ratio of 5.95. Lexeo Therapeutics has a 12 month low of $5.77 and a 12 month high of $22.33.

Lexeo Therapeutics Company Profile

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.